Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
about
Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.Gene expression and pathway analysis of human hepatocellular carcinoma cells treated with cadmiumSerine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersAssociation of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma.TMPRSS2-ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-analysis of Racial Differences.The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis.Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2.Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.DLC-1 induces mitochondrial apoptosis and epithelial mesenchymal transition arrest in nasopharyngeal carcinoma by targeting EGFR/Akt/NF-κB pathway.Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinomaTargeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance
P2860
Q27853114-1C2AAE9C-D07E-4FAD-BFE2-F692E7D8372AQ33827629-B2D77222-37B0-4933-B25A-CF2F75C602C8Q36161911-B88495D2-47DA-487E-8B25-5FA6A7F4C111Q36546449-9406ACA9-818B-4A3D-B646-D52486FCAB9EQ38921939-531AE9F0-6135-48DD-BF2B-76F31765FFC5Q39386421-55D7D59B-219E-47D6-B0C4-DAC11A973190Q41016093-C6A02AFB-414F-418D-9177-72CC704D656DQ42748239-92AC88E3-B647-4782-8B29-439120AFB119Q47438222-940DF503-70D7-47AB-8D42-EE7B1F16C91FQ48094189-8F6998D1-2470-40BC-8668-FF29CF91ED4FQ49329227-CB70AE2D-F0C2-494E-8649-517B08DE7ABFQ51395627-B9F35D3B-E480-449B-89E9-4198575758B1Q51586225-0425C7A2-0D8B-474C-AE01-7AFF8690DFE9Q53575785-9AC911DE-CD8C-465F-8745-5B1AFB8DB7C9Q58062853-F983D1CC-65A9-4D9D-808B-035AE950B5B3Q58547123-686D3877-AE5A-4EAF-8379-4E69475A70E5
P2860
Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Serine protease inhibitor Kaza ...... ng pathway in prostate cancer.
@en
Serine protease inhibitor Kaza ...... ng pathway in prostate cancer.
@nl
type
label
Serine protease inhibitor Kaza ...... ng pathway in prostate cancer.
@en
Serine protease inhibitor Kaza ...... ng pathway in prostate cancer.
@nl
prefLabel
Serine protease inhibitor Kaza ...... ng pathway in prostate cancer.
@en
Serine protease inhibitor Kaza ...... ng pathway in prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Serine protease inhibitor Kaza ...... ng pathway in prostate cancer.
@en
P2093
Chunni Wang
Jingjing Song
Weiwei Tan
Xiaoqing Yang
P2860
P304
P356
10.1002/PROS.22787
P577
2014-03-12T00:00:00Z